Renejix CDMO Partner for Small Molecule Oral Dosage Forms Renejix CDMO Partner for Small Molecule Oral Dosage Forms

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GlaxoSmithKline and MMV Present Positive Data on Treatment for Plasmodium Vivax Malaria in Children from 6 Months up to 15 Years of Age","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data Safety Monitoring Board Recommends Completion of Phase II Study to Evaluate the Efficacy and Safety of ARAKODA\u00ae (tafenoquine) for Treatment of Mild-Moderate Covid-19 Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"WallachBeth Capital LLC","pharmaFlowCategory":"D","amount":"$2.4 million","upfrontCash":"Undisclosed","newsHeadline":"60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Yale University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"60 Degrees Pharmaceuticals Signs Clinical Trial Agreements for Tafenoquine Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"60 Degrees Pharma Receives FDA ODD for Tafenoquine for Acute Babesiosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Enrolled in Tafenoquine Clinical Trial for Babesiosis at Tufts","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"GSK","sponsor":"Medicines for Malaria Venture","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK and MMV Launch New Medicine to Prevent Plasmodium vivax Malaria Relapse","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"July 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"60 Degrees Pharma Announces IRB Approval for Tafenoquine Study in Babesiosis Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals for Tafenoquine Succinate

    Menu

    Tafenoquine Succinate

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    DOSSIERs // Finished Dosage Forms

    PATENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              60 Degrees Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              60 Degrees Pharmaceuticals Signs Clinical Trial Agreements for Tafenoquine Study

              Details:

              Through the agreement, 60 Degrees will focus on advancing the development of Arakoda (tafenoquine succinate), which is being evaluated in the mid-stage clinical trial studies for treating Babesiosis.

              Lead Product(s): Tafenoquine Succinate

              Therapeutic Area: Infections and Infectious Diseases Product Name: Arakoda

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Yale University

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement July 19, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              60 Degrees Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              60 Degrees Pharma Announces IRB Approval for Tafenoquine Study in Babesiosis Patients

              Details:

              Arakoda (tafenoquine succinate) is the inhibitor of hematin polymerization which is being evaluated for the treatment of babesiosis patients.

              Lead Product(s): Tafenoquine Succinate

              Therapeutic Area: Infections and Infectious Diseases Product Name: Arakoda

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 09, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              GSK

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              GSK and MMV Launch New Medicine to Prevent Plasmodium vivax Malaria Relapse

              Details:

              Kozenis (tafenoquine) is the first single-dose, oral, hematin polymerization inhibitor co-administered with chloroquine for preventing P. vivax malaria relapse, launched in Thailand and Brazil.

              Lead Product(s): Tafenoquine Succinate,Chloroquine Phosphate

              Therapeutic Area: Infections and Infectious Diseases Product Name: Kozenis

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Medicines for Malaria Venture

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 06, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              60 Degrees Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              First Patient Enrolled in Tafenoquine Clinical Trial for Babesiosis at Tufts

              Details:

              Arakoda (tafenoquine succinate) is the inhibitor of hematin polymerization which is being evaluated in phase 2 clinical trials for the treatment of babesiosis patients.

              Lead Product(s): Tafenoquine Succinate

              Therapeutic Area: Infections and Infectious Diseases Product Name: Arakoda

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 27, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              60 Degrees Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              60 Degrees Pharma Receives FDA ODD for Tafenoquine for Acute Babesiosis

              Details:

              Arakoda (tafenoquine succinate) is the inhibitor of hematin polymerization which is being evaluated in phase 2 clinical trials for the treatment of babesiosis patients.

              Lead Product(s): Tafenoquine Succinate

              Therapeutic Area: Infections and Infectious Diseases Product Name: Arakoda

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 11, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              60 Degrees Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris

              Details:

              Arakoda (tafenoquine succinate) is a USFDA approved small molecule drug which acts as a viral replication inhibitor. It is being evaluated for the treatment of candida auris infection.

              Lead Product(s): Tafenoquine Succinate

              Therapeutic Area: Infections and Infectious Diseases Product Name: Arakoda

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 20, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              60 Degrees Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering

              Details:

              The Company intends to use the net proceeds for the relaunch of the Company’s FDA-approved Arakoda (tafenoquine) an antimalarial indicated for the prophylaxis of malaria in. patients aged 18 years and older.

              Lead Product(s): Tafenoquine Succinate

              Therapeutic Area: Infections and Infectious Diseases Product Name: Arakoda

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: WallachBeth Capital LLC

              Deal Size: $2.4 million Upfront Cash: Undisclosed

              Deal Type: Public Offering January 30, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              60 Degrees Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Data Safety Monitoring Board Recommends Completion of Phase II Study to Evaluate the Efficacy and Safety of ARAKODA® (tafenoquine) for Treatment of Mild-Moderate Covid-19 ...

              Details:

              ARAKODA (tafenoquine) has not been proven safe to treat or prevent COVID-19. Testing for G6PD (Glucose6-phosphate dehydrogenase deficiency) is mandatory before prescribing ARAKODA.

              Lead Product(s): Tafenoquine Succinate

              Therapeutic Area: Infections and Infectious Diseases Product Name: Arakoda

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 08, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              GSK

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              GlaxoSmithKline and MMV Present Positive Data on Treatment for Plasmodium Vivax Malaria in Children from 6 Months up to 15 Years of Age

              Details:

              Data from the TEACH study of tafenoquine, an 8-aminoquinoline, for the prevention of relapse of Plasmodium vivax (P. vivax) malaria in children and adolescents showed 95% of the study’s 60 subjects had no recurrence of P. vivax malaria during four months of follow-up.

              Lead Product(s): Tafenoquine Succinate

              Therapeutic Area: Infections and Infectious Diseases Product Name: Krintafel

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 19, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Post Enquiry
              POST ENQUIRY